Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 27;11(19):3011. doi: 10.3390/cells11193011

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Activation of cGAS-STING suppressed bladder cancer in cisplatin-treated C57 mice. (A) Establish of bladder cancer transplantation models in C57 mice, left. Tumor volumes of different groups, right. (B–E) Infiltration percentages of (B) CD8+, CD45+ T cells, (C) CD11b+, MHCⅡ+ DCs, (D) F4/80+, CD11c+ Macrophage, (E) CD3+, CD45+ cells in MB49 transplantation tumors. (F–J) CYBERSORT predicted infiltration percentages of CD8+ T cells (F), DCs activated cells (G), DCs resting cells (H), Macrophages M1 cells (I), and Macrophages M2 cells (J) in response group (n = 50, CR or PR) was significantly higher than non-response group (n = 30, PD or SD) after cisplatin-based chemotherapy. * p < 0.05, ** p < 0.01, *** p < 0.001. DDP, cisplatin.